Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
ZyVersa Therapeutics, Inc. (ZVSA) had Stock-Based Compensation of $0.06M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-1.79M |
|
-- |
|
-- |
|
$1.30M |
|
$-1.30M |
|
$-0.49M |
|
$-1.79M |
|
$-1.79M |
|
$-1.79M |
|
$-1.79M |
|
$-1.79M |
|
$-1.79M |
|
$-1.30M |
|
$-1.30M |
|
8.10M |
|
8.10M |
|
$-0.22 |
|
$-0.22 |
|
| Balance Sheet Financials | |
$0.74M |
|
-- |
|
-- |
|
$0.74M |
|
$14.87M |
|
-- |
|
-- |
|
$14.87M |
|
$-14.12M |
|
$-14.12M |
|
$-14.12M |
|
8.10M |
|
| Cash Flow Statement Financials | |
$-0.80M |
|
-- |
|
$1.00M |
|
$0.10M |
|
$0.30M |
|
$0.20M |
|
|
Stock-Based Compensation |
$0.06M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.05 |
|
-- |
|
-- |
|
-- |
|
-0.09 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.80M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
12.70% |
|
12.70% |
|
-241.62% |
|
12.70% |
|
$-1.74 |
|
$-0.10 |
|
$-0.10 |
|